Sec Form 4 Filing - Klein Keith @ KYTHERA BIOPHARMACEUTICALS INC - 2015-10-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Klein Keith 2. Issuer Name and Ticker or Trading Symbol KYTHERA BIOPHARMACEUTICALS INC [ KYTH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) General Counsel (Last) (First) (Middle) C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 10/01/2015 (Street) WESTLAKE VILLAGE, CA91362 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/01/2015 D 4,643 ( 2 ) D 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 4.5 10/01/2015 D 28,960 ( 3 ) 09/16/2018 Common Stock 28,960 ( 3 ) 0 D Stock Option (right to buy) $ 4.84 10/01/2015 D 13,614 ( 4 ) 01/21/2019 Common Stock 13,614 ( 4 ) 0 D Stock Option (right to buy) $ 5.9 10/01/2015 D 21,272 ( 5 ) 10/14/2020 Common Stock 21,272 ( 5 ) 0 D Stock Option (right to buy) $ 8.22 10/01/2015 D 852 ( 6 ) 02/01/2022 Common Stock 852 ( 6 ) 0 D Stock Option (right to buy) $ 27.5 10/01/2015 D 6,700 ( 7 ) 01/29/2023 Common Stock 6,700 ( 7 ) 0 D Stock Option (right to buy) $ 44.02 10/01/2015 D 15,608 ( 8 ) 01/22/2024 Common Stock 15,608 ( 8 ) 0 D Stock Option (right to buy) $ 38.53 10/01/2015 D 36,758 ( 9 ) 01/29/2025 Common Stock 36,758 ( 9 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Klein Keith C/O KYTHERA BIOPHARMACEUTICALS, INC. 30930 RUSSELL RANCH ROAD, 3RD FLOOR WESTLAKE VILLAGE, CA91362 General Counsel Signatures /s/ Keith Klein 10/02/2015 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement" and the transactions contemplated therein, the "Merger"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest. ( 2 )Includes 575 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on September 21, 2015. ( 3 )Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 7,654 shares of Allergan common stock at an exercise price of $17.00 per share. ( 4 )Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 3,598 shares of Allergan common stock at an exercise price of $18.30 per share. ( 5 )Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 5,622 shares of Allergan common stock at an exercise price of $22.31 per share. ( 6 )Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 225 shares of Allergan common stock at an exercise price of $31.11 per share. ( 7 )Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 1,770 shares of Allergan common stock at an exercise price of $104.04 per share. ( 8 )Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 4,125 shares of Allergan common stock at an exercise price of $166.55 per share. ( 9 )Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 9,715 shares of Allergan common stock at an exercise price of $145.78 per share.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.